Metabolic research has exploded over the past decade — incretin agonists, mitochondrial co-factors, lipolysis modulators, and GH-axis peptides all target different nodes of energy metabolism. Here is the comparison by mechanism and research context.
| Mechanism | Peptides | Research focus |
|---|---|---|
| Incretin agonists | GLP-1SM, GLP-2TZ, GLP-3 RT | GLP-1/GIP/GCGR signaling, adiposity, glycemic regulation |
| Lipolysis (GH-pathway) | Tesamorelin, AOD 9604, HGH fragment 176-191 | Visceral fat, GH lipolytic signaling |
| NNMT inhibition | 5-Amino-1MQ | Methyl group metabolism, SAM recycling, adiposity |
| Mitochondrial co-factor | NAD+, MOTS-c | Energy metabolism, mitochondrial signaling |
| Triple monoamine | Tesofensine | Appetite suppression, attention, motivation |
| Amylin analogue | Cagrilintide | Satiety signaling, often paired with GLP-1 |
AOD 9604 is a modified fragment of the C-terminus of human growth hormone (residues 176-191) with an N-terminal tyrosine addition. Research has examined its ability to stimulate lipolysis and inhibit lipogenesis in adipose tissue models — without activating the somatotropic pathway engaged by full-length GH.
5-Amino-1MQ is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT). NNMT transfers methyl groups from SAM (S-adenosylmethionine) to nicotinamide. Research has shown that NNMT is elevated in obese adipose tissue in mouse models, and inhibition reduces adipose mass and improves metabolic parameters in those models.
MOTS-c (Mitochondrial Open Reading frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded by the mitochondrial genome. Research has examined its role in metabolic homeostasis — it communicates mitochondrial status to the nucleus, modulating AMPK and insulin sensitivity pathways in preclinical models.
Cagrilintide is a long-acting amylin analogue. Amylin is co-secreted with insulin from pancreatic beta cells and contributes to satiety signaling. Research has examined Cagrilintide especially in combination with GLP-1 agonists (Cagri+Sema) where the combined amylin + GLP-1 pathway engagement produces larger adiposity effects than either alone in preclinical models.
Full-length human GH activates both the lipolytic pathway (fat breakdown) and the somatotropic pathway (growth, IGF-1). AOD 9604 is a modified fragment designed to isolate the lipolytic activity without the growth/IGF-1 effects. This separation is why AOD 9604 is studied specifically in adiposity contexts rather than growth contexts.
Technically 5-Amino-1MQ is a small molecule (not a peptide) — it's a quinoline derivative that inhibits the NNMT enzyme. It is included in peptide research catalogs because it targets the same metabolic research space as peptide compounds and is studied in similar preclinical models of obesity and metabolic dysfunction.
Amylin (Cagrilintide) and GLP-1 (GLP-1SM) engage different satiety pathways. Combined, they produce larger magnitude effects on food intake and body weight in preclinical comparison studies than either compound alone. This has made CagriSema one of the most-studied emerging research combinations in obesity literature.
Yes. All metabolic research compounds listed here are legal to acquire for research purposes in the United States. They are classified as research-use-only — not intended for human consumption in this form. Licensed researchers and physicians may acquire them for preclinical research and practice-of-medicine use.
Every SMART MD batch is verified by three independent U.S. laboratories via HPLC, mass spectrometry, and LAL endotoxin assay. Lot-specific COAs are publicly verifiable at smartmdpeptides.com/verify.
Check every COA before you buy. Compare to any other supplier.